Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser light shows promise for rare nerve pain

NCT ID NCT07661667

Symptom relief Sponsor: Centre Hospitalier de Cornouaille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether photobiomodulation (low-level laser therapy) can reduce pain and disability in people with anti-MAG neuropathy, a rare nerve condition. Ten participants will receive 16 laser sessions over six weeks. Researchers will measure changes in disability, pain, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
photobiomodulation (low-level laser therapy)
What this could lead to
If it works, this could offer a safe, non-drug option to reduce pain and disability from anti-MAG neuropathy.
What could go wrong
This is a very small, early study with only 10 participants, so results may not apply widely. The treatment aims to ease symptoms, not cure the underlying disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients treated at the Cornouaille Hospital in the hematology and neurology departments

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * IgM gammopathy with the presence of anti-MAG antibodies * symptomatic peripheral neuropathy * patient agreement Exclusion Criteria: * Patients with a solid tumor located in areas exposed to PBM * Patients under legal guardianship (guardianship, conservatorship...) * cognitive disorders * Peripheral neuropathy of other aetiologies * Declining to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anti-mag neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy peripheral nervous system disorder polyneuropathy associated with IgM monoclonal gammapathy with anti-MAG

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anti-mag neuropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre hospitalier de Cornouaille

    Quimper, 29107, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.